Results 91 to 100 of about 21,990 (200)

The 15th International Oncolytic Virotherapy Conference: Clinical successes point to a brighter future for cancer treatment

open access: yesMolecular Therapy: Oncology
The 15th International Oncolytic Virotherapy Conference took place in Banff, Alberta, and showcased diverse new approaches to enhancing oncolytic virus therapy. A reflective keynote highlighted industry challenges and lessons.
Jahanara Rajwani   +3 more
doaj   +1 more source

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies

open access: yesBiomedicines, 2017
Oncolytic virotherapy represents a novel therapeutic strategy in the treatment of gastrointestinal malignancies. Oncolytic viruses, including genetically engineered and naturally occurring viruses, can selectively replicate in and induce tumor cell ...
Daniel H. Ahn, Tanios Bekaii-Saab
doaj   +1 more source

Oncolytic virotherapy: the questions and the promise

open access: yesOncolytic Virotherapy, 2013
Oncolytic virotherapy is a new strategy to reduce tumor burden through selective virus replication in rapidly proliferating cells. Oncolytic viruses are members of at least ten virus families, each with its advantages and disadvantages. Here, I briefly review the recent advances and key challenges, as exemplified by the best-studied platforms.
openaire   +3 more sources

The role and mechanism of neutrophils in oncolytic virus therapy

open access: yesExperimental Biology and Medicine
Oncolytic viruses (OVs) are a class of viruses capable of specifically infecting and killing tumor cells. They exert antitumor effects through direct lysis of tumor cells, activation of the immune system, and disruption of tumor vasculature. Neutrophils,
Baixian Huang   +3 more
doaj   +1 more source

Applications of Oncolytic Virotherapy in Malignant Tumors

open access: yes
Oncolytic virotherapy, an emerging cancer immunotherapy modality, has attracted much attention in recent years due to its power to selectively infect and eradicate tumor cells while simultaneously activating host anticancer immune responses.
Yining Wang
core   +1 more source

Supplementary Fig. S2 from Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer

open access: yes, 2009
Supplementary Fig. S2 from Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung ...
Shinji Kuroda (197818)   +8 more
core   +1 more source

Current perspectives of virotherapy as a cancer treatment strategy

open access: yesИнфекция и иммунитет
Analysis of scientific literature presented in the main databases (PubMed, CyberLeninka, Google Scholar, Scopus) evidence that after cardiovascular diseases malignant tumors hold the second place among the most common causes of mortality in both ...
Lyubov D. Vlasova
doaj   +1 more source

Supplementary Fig. S1 from Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer

open access: yes, 2009
Supplementary Fig. S1 from Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung ...
Shinji Kuroda (197818)   +8 more
core   +1 more source

Emerging role of Natural killer cells in oncolytic virotherapy

open access: yes, 2015
Rauf Bhat, Jean Rommelaere Division of Tumor Virology, German Cancer Research Center, Heidelberg, Germany Abstract: Natural killer (NK) cells constitute a subtype of lymphocytes that initiate innate immune responses against tumors and virus-infected ...
Bhat R, Rommelaere J
core  

Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. [PDF]

open access: yes, 2010
The intrinsic oncolytic specificity of vesicular stomatitis virus (VSV) is currently being exploited to develop alternative therapeutic strategies for hepatocellular carcinoma (HCC). Identifying key regulators in diverse transduction pathways that define
Enrico N. De Toni   +32 more
core   +2 more sources

Home - About - Disclaimer - Privacy